Loading the section…

IBRX: financial statements from SEC — TradeAlmanac

IBRX

ImmunityBio, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/12/2025	31/12/2024
Revenue	113M	15M
Cost of revenue	753,000	0
Research and development	—	190M
Selling, general and administrative	—	169M
Operating expenses	369M	359M
Operating income	−256M	−344M
Pre-tax income	−352M	−414M
Income tax	−135,000	0
Net income	−351M	−414M
Earnings per share	−0.38	−0.59
Earnings per share, diluted	−0.38	−0.62
Weighted average shares	920M	697M
Weighted average shares, diluted	920M	700M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	205M	88M	60M	138M	61M	143M	112M	130M
Short-term investments	176M	154M	198M

Cash flow

Metric	31/12/2025	31/12/2024
Operating cash flow	−305M	−391M
Depreciation and amortisation	16M	18M
Share-based compensation	37M	34M
Capital expenditure	4M	7M
Investing cash flow	−150M	−12M
Financing cash flow	400M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator